Drugs / AZD0022
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06599502 | Oct 2024 → Oct 2025 | colorectal carcinoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | AstraZeneca | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06599502 ↗ |
| Action | Inhibit | “AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.” NCT06599502 ↗ |
| Route | Oral | “AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.” NCT06599502 ↗ |
| Target | KRAS | “AZD0022 is an oral KRASG12D inhibitor that blocks KRASG12D function in patients with this type of mutation.” NCT06599502 ↗ |